USANA Health Sciences

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates significantly due to a $29.1M non-cash goodwill impairment in the Hiya segment and persistent weakness in active customer counts. Revenue of $223.3M fell short of the $235.0M consensus, while GAAP EPS of -$1.16 was substantially below the $0.22 expected. The Hiya segment's 16.7% YoY revenue decline and the spike in the effective tax rate further pressured the bottom line, despite modest growth in the Rise segment and stability in Greater China.